Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Alzheimer's disease is the most common form of dementia. About 50 million people worldwide suffer from Alzheimer's disease(1). A further increase in the number of cases is expected by 2050, partly due to the fundamental rise in life expectancy. The clinical picture is characterised by a progressive loss of cognitive abilities. The neurological hallmarks are the presence of neuritic plaques and neurofibrillary tangles of proteins in brain tissue. Ultimately, the disease leads to death.
Here you will find a list of important antibodies, reagents, kits, and other tools you need for your research in the field of neurodegenerative diseases and especially Alzheimer's, as well as some more additional resources on the topic.
The following targets are directly related to research on Alzheimer's disease. Search Antibodies, Kits, Reagents and other products.
Amyloid beta and tau protein are two of the major players in Alzheimer's Disease research. Below you will find a handpicked selection of antibodies with human and mouse reactivity. Click on a link to get more details.
We are preparing the requested document. Please wait, this may take a while...!
See all Amyloid beta Antibodies
See all Tau Protein Antibodies
Generation of Amyloid peptide (Abeta) is at the beginning of a cascade that leads to Alzheimer's disease. Currenty, the mechanisms of Abeta generation and Abeta prevention are subject of intensive research. Amyloid precursor protein (APP), as well as beta- and gamma-secretases are the principal players involved in Abeta production, while alpha-secretase cleavage on APP prevents Abeta deposition. Inhibitors or modulators that target beta- and gamma-secretases as well as alpha-secretase activators are promising candidates for treatment of Alzheimer's disease.(3) We currently offer three kits for secretase detection.
Fibrillar deposits of highly phosphorylated tau are a key pathological feature of several neurodegenerative tauopathies including Alzheimer’s disease (AD) and some frontotemporal dementias. Increasing evidence suggests that the presence of these end-stage neurofibrillary lesions do not cause neuronal loss, but rather that alterations to soluble tau proteins induce neurodegeneration.(2)
We offer a variety of lysates for use in Western Blotting for Alzheimer's Disease research: See all products
(1) Alzheimer’s Research UK. Dementia Statistics Hub - Global Prevalence. Internet: www.dementiastatistics.org/statistics/global-prevalence/
(2) Noble W, Hanger DP, Miller CC, Lovestone S. The importance of tau phosphorylation for neurodegenerative diseases. Front Neurol. 2013 Jul 1;4:83. doi: 10.3389/fneur.2013.00083. PMID: 23847585; PMCID: PMC3696910.
(3) Epis, Marcello, Gardoni, Di Luca. Alpha, beta-and gamma-secretases in alzheimer's disease, Frontiers in Bioscience S4, 1126-1150 , January 1, 2012